|
US7041871B1
(en)
*
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
MX336813B
(es)
*
|
1996-02-09 |
2016-02-02 |
Abbvie Biotechnology Ltd |
Anticuerpos humanos que ligan el tnfa humano.
|
|
US6805869B2
(en)
|
1996-06-12 |
2004-10-19 |
Shanghai Cp Guojian Pharmaceutical Co., Ltd. |
Cellular vaccines and immunotherapeutics and methods for their preparation
|
|
US7910096B2
(en)
|
1996-11-15 |
2011-03-22 |
Trustees Of Tufts College |
Human neutralizing antibodies against hemolytic uremic syndrome
|
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
|
GB9823930D0
(en)
*
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
|
US7666609B1
(en)
|
1998-12-01 |
2010-02-23 |
Shanghai Cp Guojian Pharmaceutical Co. Ltd. |
Method and composition for diagnosis of melanocytic lesions
|
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
|
US7883704B2
(en)
*
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
NZ517331A
(en)
*
|
1999-07-29 |
2004-02-27 |
Medarex Inc |
Human monoclonal antibodies to prostate specific membrane antigen and a transgenic mouse to produce the antibody
|
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
AU7491800A
(en)
*
|
1999-09-15 |
2001-04-17 |
Therapeutic Human Polyclonals, Inc. |
Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
|
|
US7030228B1
(en)
|
1999-11-15 |
2006-04-18 |
Miltenyi Biotec Gmbh |
Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
|
|
US7820878B2
(en)
*
|
1999-11-19 |
2010-10-26 |
Kyowa Hakko Kirin Co., Ltd. |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
|
US7414170B2
(en)
*
|
1999-11-19 |
2008-08-19 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovines capable of human antibody production
|
|
US7074983B2
(en)
|
1999-11-19 |
2006-07-11 |
Kirin Beer Kabushiki Kaisha |
Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
|
|
WO2001035735A1
(en)
*
|
1999-11-19 |
2001-05-25 |
Hematech, Llc |
Production of ungulates, preferably bovines that produce human immunoglobulins
|
|
JP2001211882A
(ja)
*
|
2000-01-31 |
2001-08-07 |
Shiyuuji Miyagawa |
移植関連タンパク質をコードするコドン改変型遺伝子
|
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
|
EP1176200A3
(de)
|
2000-06-20 |
2005-01-12 |
Switch Biotech Aktiengesellschaft |
Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
|
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
AU2001297523B2
(en)
|
2000-11-17 |
2007-01-18 |
Sab, Llc |
Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
|
|
CA2430013C
(en)
|
2000-11-30 |
2011-11-22 |
Medarex, Inc. |
Transgenic transchromosomal rodents for making human antibodies
|
|
US7491534B2
(en)
|
2000-12-22 |
2009-02-17 |
Kirin Holdings Kabushiki Kaisha |
Methods for altering cell fate to generate T-cells specific for an antigen of interest
|
|
US20020142397A1
(en)
*
|
2000-12-22 |
2002-10-03 |
Philippe Collas |
Methods for altering cell fate
|
|
MXPA03005624A
(es)
|
2000-12-22 |
2004-12-03 |
Vaurox Llc |
Metodos para clonar mamiferos usando cromatina reprogramada del donador o celulas donadoras.
|
|
NZ527977A
(en)
|
2001-02-12 |
2005-10-28 |
Medarex Inc |
Human monoclonal antibodies to FC alpha receptor (CD89)
|
|
CN1789416B
(zh)
*
|
2001-05-11 |
2011-11-16 |
协和发酵麒麟株式会社 |
含人抗体λ轻链基因的人类人工染色体
|
|
GB0115256D0
(en)
*
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
|
US7084257B2
(en)
*
|
2001-10-05 |
2006-08-01 |
Amgen Inc. |
Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
JP5355839B2
(ja)
|
2001-10-23 |
2013-11-27 |
ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． |
Ｐｓｍａ抗体およびタンパク質マルチマー
|
|
EP2319301B1
(en)
|
2001-11-30 |
2017-09-06 |
Amgen Fremont Inc. |
Transgenic animals bearing human Ig lambda light chain genes
|
|
JP4238138B2
(ja)
*
|
2001-12-22 |
2009-03-11 |
４−アンチボディ アーゲー |
遺伝的に修飾された脊椎動物前駆体リンパ球の生成方法及び異種結合タンパク質の産生を目的としたその使用。
|
|
IL162835A0
(en)
|
2002-01-09 |
2005-11-20 |
Medarex Inc |
Human monoclonal antibodies against cd30
|
|
SI1485477T1
(sl)
|
2002-02-25 |
2009-10-31 |
Genentech Inc |
Novi citokinski receptor GLM-R tipa 1
|
|
US7718776B2
(en)
|
2002-04-05 |
2010-05-18 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
|
NZ536420A
(en)
|
2002-04-12 |
2008-04-30 |
Medarex Inc |
Methods of treatment using CTLA-4 antibodies
|
|
GB2387599B
(en)
*
|
2002-04-17 |
2005-08-10 |
Jason Peter Brown |
Methods for producing antibodies
|
|
CN1668187A
(zh)
|
2002-05-17 |
2005-09-14 |
赫马技术有限公司 |
能够产生人抗体的转基因有蹄动物
|
|
EP1506286B1
(en)
|
2002-05-24 |
2014-03-19 |
Merck Sharp & Dohme Corp. |
Neutralizing human anti-igfr antibody
|
|
KR101317045B1
(ko)
|
2002-09-06 |
2013-10-16 |
암젠 인코포레이티드 |
치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
|
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
|
BRPI0315295C1
(pt)
|
2002-10-17 |
2021-05-25 |
Genmab As |
anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
|
|
US20060200871A1
(en)
*
|
2002-10-21 |
2006-09-07 |
Van Ness Brian G |
Transgenic non-human animals with expanded mature b cell and plasma cell populations
|
|
US7429690B2
(en)
|
2002-11-08 |
2008-09-30 |
Kirin Holdings Kabushiki Kaisha |
Transgenic bovines having reduced prion protein production
|
|
US7438907B2
(en)
|
2002-11-15 |
2008-10-21 |
Genmab A/S |
Human monoclonal antibodies against CD25
|
|
US7285269B2
(en)
|
2002-12-02 |
2007-10-23 |
Amgen Fremont, Inc. |
Antibodies directed to tumor necrosis factor
|
|
NZ541050A
(en)
|
2002-12-16 |
2010-06-25 |
Genmab As |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
|
US9259459B2
(en)
|
2003-01-31 |
2016-02-16 |
Celldex Therapeutics Inc. |
Antibody vaccine conjugates and uses therefor
|
|
ATE552860T1
(de)
|
2003-01-31 |
2012-04-15 |
Celldex Res Corp |
Antikörper-vakzine-konjugate und ihre verwendungen
|
|
WO2004084823A2
(en)
|
2003-03-19 |
2004-10-07 |
Abgenix, Inc. |
Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
|
|
AU2004232362C1
(en)
|
2003-04-23 |
2008-05-29 |
E. R. Squibb & Sons, L.L.C. |
Compositions and methods for the therapy of inflammatory bowel disease
|
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
|
KR20130065723A
(ko)
|
2003-06-27 |
2013-06-19 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
|
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
|
AR045056A1
(es)
*
|
2003-07-15 |
2005-10-12 |
Amgen Inc |
Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
|
|
EP1498133A1
(en)
|
2003-07-18 |
2005-01-19 |
Aventis Pharma Deutschland GmbH |
Use of a pak inhibitor for the treatment of a joint disease
|
|
MXPA06000798A
(es)
|
2003-07-22 |
2006-04-07 |
Schering Ag |
Anticuerpos de rg1 y usos de los mismos.
|
|
WO2005047459A2
(en)
|
2003-08-04 |
2005-05-26 |
University Of Massachusetts |
Sars nucleic acids, proteins, antibodies, and uses thereof
|
|
CN1838968A
(zh)
|
2003-08-08 |
2006-09-27 |
艾伯吉尼斯公司 |
针对甲状旁腺激素(pth)之抗体和其用途
|
|
DE602004025157D1
(de)
|
2003-09-23 |
2010-03-04 |
Univ North Carolina |
Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
|
|
DE602004026897D1
(de)
|
2003-10-14 |
2010-06-10 |
Baxter Healthcare Sa |
Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
|
|
US7326567B2
(en)
|
2003-11-12 |
2008-02-05 |
Schering Corporation |
Plasmid system for multigene expression
|
|
US7642341B2
(en)
|
2003-12-18 |
2010-01-05 |
Merck Serono S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
|
|
EP1533617A1
(en)
|
2003-11-19 |
2005-05-25 |
RMF Dictagene S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
|
|
TW200526684A
(en)
*
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
|
KR101225299B1
(ko)
|
2003-12-10 |
2013-01-24 |
메다렉스, 인코포레이티드 |
인터페론 알파 항체 및 그의 용도
|
|
PL1691837T3
(pl)
|
2003-12-10 |
2012-11-30 |
Squibb & Sons Llc |
IP-10 przeciwciała i ich zastosowanie
|
|
DK2270045T3
(en)
|
2004-02-06 |
2015-04-07 |
Univ Massachusetts |
ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
|
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
|
PT1737891E
(pt)
|
2004-04-13 |
2013-04-16 |
Hoffmann La Roche |
Anticorpos anti p-selectina
|
|
US7850962B2
(en)
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
|
AU2005237494B2
(en)
*
|
2004-04-22 |
2010-06-10 |
Kyowa Hakko Kirin Co., Ltd |
Transgenic animals and uses thereof
|
|
EP1740617B1
(en)
|
2004-04-23 |
2013-10-16 |
BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
|
TW200607523A
(en)
|
2004-06-01 |
2006-03-01 |
Domantis Ltd |
Drug compositions, fusions and conjugates
|
|
CA2568661A1
(en)
|
2004-06-03 |
2006-01-05 |
Medarex, Inc. |
Human monoclonal antibodies to fc gamma receptor i (cd64)
|
|
US7662381B2
(en)
|
2004-06-21 |
2010-02-16 |
Medarex, Inc. |
Interferon alpha receptor 1 antibodies and their uses
|
|
AU2005259221B2
(en)
|
2004-07-01 |
2011-02-10 |
Innate Pharma |
Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
|
|
WO2006003179A2
(en)
|
2004-07-01 |
2006-01-12 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
|
WO2006015373A2
(en)
|
2004-08-04 |
2006-02-09 |
Amgen Inc |
Antibodies to dkk-1
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
WO2006039644A2
(en)
|
2004-10-01 |
2006-04-13 |
Medarex, Inc. |
Methods of treating cd30 positive lymphomas
|
|
US7785591B2
(en)
*
|
2004-10-14 |
2010-08-31 |
Morphosys Ag |
Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
|
|
CA2958259C
(en)
|
2004-10-22 |
2020-06-30 |
Revivicor, Inc. |
Ungulates with genetically modified immune systems
|
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
|
EP1824886B1
(en)
|
2004-11-17 |
2010-12-22 |
Amgen Inc. |
Fully human monoclonal antibodies to il-13
|
|
CN101128487B
(zh)
|
2004-12-02 |
2012-10-10 |
杜门蒂斯有限公司 |
靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
|
|
PT1828249E
(pt)
*
|
2004-12-03 |
2011-02-25 |
Schering Corp |
Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
|
|
CA2592249C
(en)
|
2004-12-20 |
2014-07-29 |
Amgen Fremont Inc. |
Binding proteins specific for human matriptase
|
|
ZA200705695B
(en)
|
2004-12-21 |
2009-02-25 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
EP2361933A3
(en)
|
2005-01-26 |
2012-05-02 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
|
ES2498794T3
(es)
|
2005-02-18 |
2014-09-25 |
Medarex, L.L.C. |
Anticuerpos monoclonales contra CD30 que carecen de restos fucosilo
|
|
EP1861711B1
(en)
|
2005-03-11 |
2012-01-11 |
Sanofi |
Use of mgc4504
|
|
CA2601574C
(en)
|
2005-03-15 |
2014-12-02 |
University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin k-dependent proteins
|
|
JP5225069B2
(ja)
|
2005-03-23 |
2013-07-03 |
ゲンマブ エー／エス |
多発性骨髄腫の治療のためのｃｄ３８に対する抗体
|
|
JP4875064B2
(ja)
*
|
2005-04-15 |
2012-02-15 |
シェーリング コーポレイション |
癌を処置または予防するための方法および組成物
|
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
EP1882044A1
(en)
|
2005-05-11 |
2008-01-30 |
sanofi-aventis |
Use of a gip promoter polymorphism
|
|
EP1915394B1
(en)
|
2005-05-20 |
2021-01-27 |
Lonza Biologics plc. |
High-level expression of recombinant antibody in a mammalian host cell
|
|
EP1893756B1
(en)
*
|
2005-06-08 |
2015-08-12 |
The Regents of The University of California |
Elimination of n-glycolylneuraminic acid from mammalian products for human use
|
|
NZ564098A
(en)
*
|
2005-06-15 |
2010-04-30 |
Schering Corp |
Anti-IGF1R antibody formulations
|
|
SI2452694T1
(sl)
|
2005-06-30 |
2019-05-31 |
Janssen Biotech, Inc. |
Protitelesa proti-IL-23, sestavki in postopki uporabe
|
|
PT1907424E
(pt)
*
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
EP2397498A3
(en)
|
2005-07-18 |
2013-11-27 |
Amgen, Inc |
Human anti-B7RP1 neutralizing antibodies
|
|
NZ566395A
(en)
|
2005-09-26 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to CD70
|
|
DE102005048898A1
(de)
|
2005-10-12 |
2007-04-19 |
Sanofi-Aventis Deutschland Gmbh |
EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
|
|
WO2007045477A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Human antibodies against il-13 and therapeutic uses
|
|
EP1957115B8
(en)
|
2005-11-10 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
|
HRP20140240T4
(hr)
|
2005-11-30 |
2017-02-24 |
Abbvie Inc. |
Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
|
|
US8110194B2
(en)
|
2005-12-07 |
2012-02-07 |
Medarex, Inc. |
CTLA-4 antibody dosage escalation regimens
|
|
US8383118B2
(en)
|
2005-12-08 |
2013-02-26 |
Medarex, Inc. |
Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
|
|
DK1979001T3
(da)
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
SG10201400426XA
(en)
|
2006-01-12 |
2014-07-30 |
Alexion Pharma Inc |
Antibodies to ox-2/cd200 and uses thereof
|
|
US20090175886A1
(en)
|
2006-01-17 |
2009-07-09 |
Medarex, Inc. |
Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
|
|
WO2007109749A2
(en)
*
|
2006-03-21 |
2007-09-27 |
Wyeth |
Methods for preventing and treating amyloidogenic diseases
|
|
AU2007235496B2
(en)
|
2006-03-31 |
2013-11-21 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
|
KR20090029184A
(ko)
|
2006-04-07 |
2009-03-20 |
더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
항체 조성물 및 신생물성 질병의 치료 방법
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
EP2064244B1
(en)
|
2006-08-03 |
2019-06-05 |
MedImmune Limited |
ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF
|
|
JP5244785B2
(ja)
|
2006-08-11 |
2013-07-24 |
小野薬品工業株式会社 |
ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
|
|
CA2662350A1
(en)
|
2006-09-05 |
2008-03-13 |
Medarex, Inc. |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
|
WO2008037257A2
(en)
|
2006-09-26 |
2008-04-03 |
Genmab A/S |
Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
|
|
CA2663243A1
(en)
|
2006-09-28 |
2008-04-03 |
Merck Serono S.A. |
Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
|
|
MX2009003306A
(es)
|
2006-10-02 |
2009-04-23 |
Medarex Inc |
Anticuerpos humanos que se unen a cxcr4 y sus usos.
|
|
AU2007319605B2
(en)
|
2006-10-19 |
2011-02-17 |
Csl Limited |
Anti-IL-13R alpha 1 antibodies and their uses thereof
|
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
|
EP2097447A4
(en)
|
2006-11-15 |
2010-12-29 |
Medarex Inc |
HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
|
|
HU0700534D0
(en)
*
|
2006-11-24 |
2007-10-29 |
Mezoegazdasagi Biotechnologiai |
Transgenic animal with enhanced immune response and method for the preparation thereof
|
|
US8481683B2
(en)
|
2006-12-01 |
2013-07-09 |
Medarex, Inc. |
Human antibodies that bind CD22 and uses thereof
|
|
EP2104501B1
(en)
*
|
2006-12-13 |
2014-03-12 |
Merck Sharp & Dohme Corp. |
Methods of cancer treatment with igf1r inhibitors
|
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
|
MX2009006277A
(es)
|
2006-12-14 |
2009-07-24 |
Medarex Inc |
Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
|
|
KR20090100461A
(ko)
*
|
2007-01-16 |
2009-09-23 |
아보트 러보러터리즈 |
건선의 치료방법
|
|
KR101598229B1
(ko)
|
2007-02-16 |
2016-02-26 |
메리맥 파마슈티컬즈, 인크. |
Ｅｒｂｂ3에 대한 항체 및 이의 용도
|
|
JP5642972B2
(ja)
|
2007-02-21 |
2014-12-17 |
ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ |
Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
|
|
AU2008223541B2
(en)
*
|
2007-03-02 |
2012-04-05 |
Amgen Inc. |
Methods and compositions for treating tumor diseases
|
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
|
ME00832B
(me)
|
2007-03-22 |
2012-03-20 |
Ucb Biopharma Sprl |
Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
|
|
ES2593484T3
(es)
|
2007-03-29 |
2016-12-09 |
Genmab A/S |
Anticuerpos biespecíficos y métodos de producción de los mismos
|
|
FI20075278A0
(fi)
|
2007-04-20 |
2007-04-20 |
Biotie Therapies Corp |
Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
|
|
WO2008145140A2
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
|
JP6071165B2
(ja)
|
2007-05-31 |
2017-02-01 |
ゲンマブ エー／エス |
安定なＩｇＧ４抗体
|
|
LT2631248T
(lt)
|
2007-06-15 |
2018-04-25 |
Medigene Ag |
Navikų gydymas, naudojant specifinį anti-l1 antikūną
|
|
EP2023144A1
(en)
|
2007-08-01 |
2009-02-11 |
Sanofi-Aventis |
Novel AS160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
|
|
ES2453592T3
(es)
|
2007-08-02 |
2014-04-08 |
Novimmune Sa |
Anticuerpos anti-RANTES y métodos de uso de los mismos
|
|
JP5588866B2
(ja)
|
2007-08-10 |
2014-09-10 |
メダレックス エル．エル．シー． |
Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
|
|
PL2188313T3
(pl)
|
2007-08-21 |
2018-04-30 |
Amgen, Inc. |
Białka wiążące ludzki antygen c-fms
|
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
JP5607530B2
(ja)
|
2007-09-04 |
2014-10-15 |
コンピュゲン エルティーディー． |
ポリペプチド並びにポリヌクレオチド、並びに薬剤および生物製剤生産のための薬剤標的としてのその利用
|
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
|
EP2497783A3
(en)
|
2007-09-26 |
2013-04-17 |
U3 Pharma GmbH |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
|
|
BRPI0820327A2
(pt)
|
2007-11-02 |
2020-10-06 |
Novartis Ag |
moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
|
|
CN101888856B
(zh)
|
2007-11-07 |
2014-08-27 |
塞尔德克斯医疗公司 |
结合人树突和上皮细胞205(dec-205)的抗体
|
|
JP5769969B2
(ja)
|
2007-11-12 |
2015-08-26 |
ユー３・ファーマ・ゲーエムベーハー |
Ａｘｌ抗体
|
|
EP2220247A4
(en)
|
2007-11-16 |
2011-10-26 |
Nuvelo Inc |
ANTIBODY AGAINST LRP6
|
|
PT2594590E
(pt)
|
2007-12-14 |
2015-01-14 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
|
AU2008337517B2
(en)
|
2007-12-14 |
2014-06-26 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
|
KR101720760B1
(ko)
|
2008-01-25 |
2017-03-28 |
오르후스 우니베르시테트 |
Ｉｇｆｂｐ-4에 대한 ｐａｐｐ-ａ 활성의 선택적 엑소사이트 억제
|
|
EP2650017A3
(en)
|
2008-02-05 |
2014-01-22 |
Bristol-Myers Squibb Company |
Alpha 5 - beta 1 antibodies and their uses
|
|
WO2009117289A2
(en)
|
2008-03-18 |
2009-09-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
|
EP2105742A1
(en)
|
2008-03-26 |
2009-09-30 |
Sanofi-Aventis |
Use of cathepsin C
|
|
EP2307042B1
(en)
|
2008-06-25 |
2014-03-26 |
H. Lundbeck A/S |
Modulation of the trpv : vps10p-domain receptor system for the treatment of pain
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
KR20160116056A
(ko)
|
2008-08-14 |
2016-10-06 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
항-ｉｌ-12/ｉｌ-23 항체
|
|
AU2009294415B2
(en)
|
2008-09-19 |
2015-09-24 |
Medimmune Llc |
Antibodies directed to DLL4 and uses thereof
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
AU2009298458B2
(en)
|
2008-09-30 |
2015-10-08 |
Ablexis, Llc |
Non-human mammals for the production of chimeric antibodies
|
|
DK2348827T3
(en)
|
2008-10-27 |
2015-07-20 |
Revivicor Inc |
IMMUNICIPLY COMPROMATED PETS
|
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
JP5611222B2
(ja)
|
2008-11-26 |
2014-10-22 |
アムジエン・インコーポレーテツド |
アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用
|
|
AU2009324092A1
(en)
|
2008-12-03 |
2011-06-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
|
US20110311450A1
(en)
|
2008-12-08 |
2011-12-22 |
Zurit Levine |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
|
EP3165537A1
(en)
|
2008-12-19 |
2017-05-10 |
H. Lundbeck A/S |
Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
|
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
|
EP2219029A1
(en)
|
2009-01-30 |
2010-08-18 |
Sanofi-Aventis |
Test systems, methods and uses involving AS160 protein
|
|
CN102341412B
(zh)
|
2009-03-05 |
2018-01-05 |
梅达雷克斯有限责任公司 |
特异于cadm1 的全人抗体
|
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
|
EP3831407A1
(en)
|
2009-04-08 |
2021-06-09 |
LipUm AB |
New methods for treatment of inflammatory diseases
|
|
US9062116B2
(en)
|
2009-04-23 |
2015-06-23 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
|
PE20120532A1
(es)
|
2009-04-27 |
2012-05-18 |
Novartis Ag |
ANTICUERPOS ANTI-ActRIIB
|
|
JP2012524524A
(ja)
|
2009-04-27 |
2012-10-18 |
ノバルティス アーゲー |
ＩＬ−１２レセプターβ１サブユニットに特異的な治療用抗体の組成物および使用方法
|
|
SG175436A1
(en)
|
2009-05-04 |
2011-12-29 |
Abbott Res Bv |
Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
|
|
CN102458437B
(zh)
|
2009-05-05 |
2015-06-10 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
|
WO2010151632A1
(en)
|
2009-06-25 |
2010-12-29 |
Bristol-Myers Squibb Company |
Protein purifacation by caprylic acid (octanoic acid ) precipitation
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
DK3622815T3
(da)
|
2009-07-08 |
2023-06-26 |
Kymab Ltd |
Gnavermodeller og terapeutiske molekyler
|
|
BR112012007875A2
(pt)
|
2009-07-31 |
2016-11-22 |
Medarex Inc |
anticorpos totalmente humanos para btla
|
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
|
EP2293072A1
(en)
|
2009-08-31 |
2011-03-09 |
Sanofi-Aventis |
Use of cathepsin H
|
|
SG179135A1
(en)
*
|
2009-09-14 |
2012-05-30 |
Abbott Lab |
Methods for treating psoriasis
|
|
EP2480561B1
(en)
|
2009-09-23 |
2016-07-13 |
E. R. Squibb & Sons, L.L.C. |
Cation exchange chromatography
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
US9588121B2
(en)
|
2009-11-06 |
2017-03-07 |
Go Therapeutics, Inc. |
Method for early detection of cancer
|
|
CA2780153A1
(en)
|
2009-11-09 |
2011-05-12 |
Alexion Pharmaceuticals, Inc. |
Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
|
|
EP2896632B1
(en)
|
2009-11-13 |
2017-10-25 |
Daiichi Sankyo Europe GmbH |
Material and methods for treating or preventing HER-3 associated diseases
|
|
CA3061784C
(en)
|
2009-11-13 |
2023-09-26 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
|
EP3255153A1
(en)
|
2009-11-17 |
2017-12-13 |
E. R. Squibb & Sons, L.L.C. |
Methods for enhanced protein production
|
|
PL2504364T3
(pl)
|
2009-11-24 |
2017-12-29 |
Medimmune Limited |
Ukierunkowane środki wiążące przeciwko B7-H1
|
|
EP2507265B1
(en)
|
2009-12-01 |
2016-05-11 |
Compugen Ltd. |
Antibody specific for heparanase splice variant T5 and its use.
|
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
|
SG182408A1
(en)
|
2010-01-11 |
2012-08-30 |
Alexion Pharma Inc |
Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
|
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Ｃｄ２０ 항체 및 이의 용도
|
|
PT3904391T
(pt)
|
2010-03-10 |
2024-10-14 |
Genmab As |
Anticorpos monoclonais contra c-met
|
|
AU2011227335B2
(en)
|
2010-03-17 |
2014-11-06 |
Abbott Research B.V. |
Anti-nerve growth factor (NGF) antibody compositions
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
MX374075B
(es)
|
2010-03-26 |
2025-03-05 |
Dartmouth College |
Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
ES2984483T3
(es)
|
2010-03-31 |
2024-10-29 |
Ablexis Llc |
Ingeniería genética de ratones para la producción de anticuerpos quiméricos
|
|
EA201690310A1
(ru)
|
2010-04-13 |
2016-12-30 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
|
CA2796055A1
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
Human fgf receptor and .beta.-klotho binding proteins
|
|
HRP20241208T1
(hr)
|
2010-04-20 |
2024-11-22 |
Genmab A/S |
Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
|
|
MX340696B
(es)
|
2010-04-30 |
2016-07-21 |
Alexion Pharma Inc |
Anticuerpos anti-c5a y metodos para usar los anticuerpos.
|
|
EP2566512A1
(en)
|
2010-05-04 |
2013-03-13 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
PH12012502193A1
(en)
|
2010-05-06 |
2021-08-09 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
EP2566892B1
(en)
|
2010-05-06 |
2017-12-20 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
EP2576621B1
(en)
|
2010-05-27 |
2019-04-10 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
SMT202000031T1
(it)
|
2010-06-09 |
2020-03-13 |
Genmab As |
Anticorpi contro cd38 umano
|
|
BR112012031727B1
(pt)
|
2010-06-15 |
2022-03-29 |
Genmab A/S |
Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
|
|
US20130189268A1
(en)
|
2010-06-22 |
2013-07-25 |
Precision Biologics, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
|
SG186397A1
(en)
|
2010-06-22 |
2013-01-30 |
Univ Colorado Regents |
Antibodies to the c3d fragment of complement component 3
|
|
WO2012018404A2
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
|
AU2011290672B2
(en)
|
2010-08-20 |
2015-07-09 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
WO2012035518A1
(en)
|
2010-09-17 |
2012-03-22 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
|
ES2719624T3
(es)
|
2010-09-23 |
2019-07-11 |
Prec Biologics Inc |
Peptidomiméticos de cáncer de colon y de páncreas
|
|
EP2625203A1
(en)
|
2010-10-05 |
2013-08-14 |
Novartis AG |
Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
|
|
KR101920250B1
(ko)
|
2010-10-13 |
2018-11-20 |
얀센 바이오테크 인코포레이티드 |
인간 온코스타틴 m 항체 및 이용 방법
|
|
CA2815181C
(en)
|
2010-10-27 |
2020-09-15 |
William Gleason Richards |
Dkk1 antibodies and methods of use
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
UY33807A
(es)
|
2010-12-17 |
2012-07-31 |
Sanofi Sa |
miRNAs como indicadores del estado tisular o de enfermedades como osteoartritis
|
|
TW201238974A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
|
TW201241179A
(en)
|
2010-12-17 |
2012-10-16 |
Sanofi Sa |
MiRNAs in joint disease
|
|
TW201239097A
(en)
|
2010-12-17 |
2012-10-01 |
Sanofi Sa |
MiRNAs in joint disease
|
|
US9631002B2
(en)
|
2010-12-21 |
2017-04-25 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for producing active vitamin K-dependent proteins
|
|
AU2012205384B2
(en)
|
2011-01-14 |
2015-09-10 |
Five Prime Therapeutics, Inc. |
IL-27 antagonists for treating inflammatory diseases
|
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
|
WO2012106634A1
(en)
|
2011-02-03 |
2012-08-09 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-cd200 antibody for prolonging the survival of allografts
|
|
US8906635B2
(en)
|
2011-02-28 |
2014-12-09 |
Northshore University Healthsystem |
Methods of diagnosing Clostridium difficile infection
|
|
EA201391248A1
(ru)
|
2011-03-01 |
2014-05-30 |
Эмджен Инк. |
Биспецифические связывающие агенты
|
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
|
US9499610B2
(en)
|
2011-04-08 |
2016-11-22 |
H. Lundbeck A/S |
Antibodies specific to pyroglutamated Aβ
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
NZ713461A
(en)
|
2011-04-15 |
2017-02-24 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
EP4520771A3
(en)
|
2011-04-20 |
2025-07-16 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
CN103796678B
(zh)
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|
|
EP2518157A1
(en)
|
2011-04-26 |
2012-10-31 |
Sanofi |
Test Systems and methods for identifying a compound altering cellular DDR activity
|
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
EP2520292A1
(en)
|
2011-05-06 |
2012-11-07 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
|
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
ES2765874T3
(es)
|
2011-05-25 |
2020-06-11 |
Innate Pharma Sa |
Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
US20140227265A1
(en)
|
2011-06-17 |
2014-08-14 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
|
EP2537532A1
(en)
|
2011-06-22 |
2012-12-26 |
J. Stefan Institute |
Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
|
|
US9428574B2
(en)
|
2011-06-30 |
2016-08-30 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
JP6472999B2
(ja)
|
2011-07-01 |
2019-02-20 |
ノバルティス アーゲー |
代謝障害を治療するための方法
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
JP6454547B2
(ja)
|
2011-07-06 |
2019-01-16 |
ゲンマブ エー／エス |
抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
|
|
WO2013010955A1
(en)
|
2011-07-15 |
2013-01-24 |
Morphosys Ag |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
|
|
WO2013012855A1
(en)
|
2011-07-18 |
2013-01-24 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
WO2013054307A2
(en)
|
2011-10-14 |
2013-04-18 |
Novartis Ag |
Antibodies and methods for wnt pathway-related diseases
|
|
SG11201401422VA
(en)
|
2011-10-27 |
2014-09-26 |
Genmab As |
Production of heterodimeric proteins
|
|
US10598653B2
(en)
|
2011-11-01 |
2020-03-24 |
Bionomics Inc. |
Methods of blocking cancer stem cell growth
|
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
|
US9221907B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Anti-GPR49 monoclonal antibodies
|
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
|
PE20141937A1
(es)
|
2011-11-16 |
2014-12-18 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
EP3590538A1
(en)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
CN104105709A
(zh)
|
2011-12-05 |
2014-10-15 |
诺华股份有限公司 |
抗her3的结构域ii的表皮生长因子受体3(her3)抗体
|
|
JP6635655B2
(ja)
|
2011-12-08 |
2020-01-29 |
アムジエン・インコーポレーテツド |
ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
|
|
HK1203384A1
(en)
|
2011-12-19 |
2015-12-11 |
Amgen Inc. |
Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
|
|
ES2728278T3
(es)
|
2011-12-21 |
2019-10-23 |
Novartis Ag |
Composiciones que comprenden anticuerpos dirigidos al factor P y C5
|
|
CA2848985A1
(en)
|
2012-02-01 |
2013-08-08 |
Compugen Ltd. |
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
KR102100388B1
(ko)
|
2012-02-06 |
2020-04-13 |
인히브릭스, 인크. |
Cd47 항체 및 그 사용 방법
|
|
NZ629697A
(en)
|
2012-03-15 |
2017-01-27 |
Janssen Biotech Inc |
Human anti-cd27 antibodies, methods and uses
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
|
US9926373B2
(en)
|
2012-04-27 |
2018-03-27 |
Novo Nordisk A/S |
Human CD30 ligand antigen binding proteins
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
|
NZ703724A
(en)
|
2012-06-11 |
2017-06-30 |
Amgen Inc |
Dual receptor antagonistic antigen-binding proteins and uses thereof
|
|
JP6285923B2
(ja)
|
2012-06-22 |
2018-02-28 |
トラスティーズ・オブ・ダートマス・カレッジ |
新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
|
WO2014016737A1
(en)
|
2012-07-24 |
2014-01-30 |
Pfizer Inc. |
Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
|
|
JP2015535212A
(ja)
|
2012-08-17 |
2015-12-10 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト |
補体活性化を検出するための組成物および方法
|
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
HK1211981A1
(en)
|
2012-09-02 |
2016-06-03 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
|
US9376489B2
(en)
|
2012-09-07 |
2016-06-28 |
Novartis Ag |
IL-18 binding molecules
|
|
US9381244B2
(en)
|
2012-09-07 |
2016-07-05 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
|
CN104903349B
(zh)
|
2012-11-08 |
2018-10-19 |
十一生物治疗股份有限公司 |
Il-6拮抗剂及其应用
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
DK2928921T3
(da)
|
2012-12-05 |
2021-04-19 |
Novartis Ag |
Sammensætninger og fremgangsmåder til antistoffer målrettet epo
|
|
TW201427989A
(zh)
|
2012-12-18 |
2014-07-16 |
Novartis Ag |
長效性蛋白質之組合物及方法
|
|
CA2896723C
(en)
|
2012-12-28 |
2024-02-13 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
|
KR20200024345A
(ko)
|
2013-01-10 |
2020-03-06 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
AU2014212014A1
(en)
|
2013-02-01 |
2015-08-27 |
Amgen Inc. |
Administration of an anti-activin-A compound to a subject
|
|
NZ710695A
(en)
|
2013-02-06 |
2020-05-29 |
Inhibrx Inc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
|
LT2953969T
(lt)
|
2013-02-08 |
2019-12-10 |
Novartis Ag |
Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
|
|
HK1207960A1
(en)
|
2013-03-12 |
2016-02-19 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
|
PH12022550138A1
(en)
|
2013-03-13 |
2023-03-06 |
Amgen Inc |
Proteins specific for baff and b7rp1 and uses thereof
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
EP3611189A1
(en)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antibodies against notch 3
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
EP2970451A1
(en)
|
2013-03-14 |
2016-01-20 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
|
CA2906737C
(en)
|
2013-03-15 |
2023-08-15 |
Amgen Inc. |
Human pac1 antibodies
|
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
|
PL2970449T3
(pl)
|
2013-03-15 |
2020-04-30 |
Amgen Research (Munich) Gmbh |
Jednołańcuchowe cząsteczki wiążące zawierające N-końcowy ABP
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
WO2014186877A1
(en)
|
2013-05-24 |
2014-11-27 |
Uger Marni Diane |
FasR ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
US10077304B2
(en)
|
2013-08-14 |
2018-09-18 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled receptor
|
|
HK1219280A1
(zh)
|
2013-08-14 |
2017-03-31 |
Novartis Ag |
治疗偶发性包涵体肌炎之方法
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
AU2014330922A1
(en)
|
2013-10-01 |
2016-03-03 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
WO2015097536A2
(en)
|
2013-12-24 |
2015-07-02 |
Janssen Pharmaceutical Nv |
Anti-vista antibodies and fragments
|
|
CA2944649C
(en)
|
2014-04-04 |
2022-06-21 |
Bionomics, Inc. |
Humanized antibodies that bind lgr5
|
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
|
PE20170441A1
(es)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
|
|
US11123426B2
(en)
|
2014-06-11 |
2021-09-21 |
The Trustees Of Dartmouth College |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
SG11201610672YA
(en)
|
2014-06-23 |
2017-01-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
|
US20170327553A1
(en)
|
2014-06-25 |
2017-11-16 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
AU2015279712B2
(en)
|
2014-06-26 |
2021-03-25 |
Yale University |
Compositions and methods to regulate renalase in the treatment of diseases and disorders
|
|
CN107073297B
(zh)
|
2014-07-08 |
2021-09-14 |
纽约大学 |
Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
|
|
SMT202000265T1
(it)
|
2014-07-11 |
2020-07-08 |
Genmab As |
Anticorpi che legano axl
|
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
MX384418B
(es)
|
2014-07-31 |
2025-03-14 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
|
|
US20170226209A1
(en)
|
2014-08-01 |
2017-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An anti-cd45rc antibody for use as drug
|
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
|
WO2016020880A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
|
EP4108256A1
(en)
|
2014-08-11 |
2022-12-28 |
University of Massachusetts |
Anti-ospa antibodies and methods of use
|
|
TW201618775A
(zh)
|
2014-08-11 |
2016-06-01 |
艾森塔製藥公司 |
Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物
|
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
WO2016044588A1
(en)
|
2014-09-19 |
2016-03-24 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
|
JP2017531642A
(ja)
|
2014-10-03 |
2017-10-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
エボラ糖タンパク質に結合する抗体およびその使用
|
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
|
EP3212670B1
(en)
|
2014-10-29 |
2020-12-23 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
US10738078B2
(en)
|
2014-11-03 |
2020-08-11 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
|
SI3215527T1
(sl)
|
2014-11-05 |
2025-04-30 |
Annexon, Inc. |
Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
|
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
|
JP6594438B2
(ja)
|
2014-11-07 |
2019-10-23 |
セセン バイオ， インコーポレイテッド |
改善されたｉｌ−６抗体
|
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
FI3218005T3
(fi)
|
2014-11-12 |
2023-03-31 |
Seagen Inc |
Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
|
|
AU2015349878A1
(en)
|
2014-11-21 |
2017-05-25 |
Bristol-Myers Squibb Company |
Antibodies against CD73 and uses thereof
|
|
CA2969730A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
|
WO2016097865A1
(en)
|
2014-12-19 |
2016-06-23 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
MX2017008218A
(es)
|
2014-12-22 |
2017-10-18 |
Five Prime Therapeutics Inc |
Anticuerpos anti-csf1r para tratar pvns.
|
|
JP6180663B2
(ja)
|
2014-12-23 |
2017-08-16 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｉｇｉｔに対する抗体
|
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
WO2016149088A1
(en)
|
2015-03-13 |
2016-09-22 |
Bristol-Myers Squibb Company |
Use of alkaline washes during chromatography to remove impurities
|
|
US20180105554A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran sulfate to enhance protein a affinity chromatography
|
|
WO2016153983A1
(en)
|
2015-03-20 |
2016-09-29 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
|
AU2016249981B2
(en)
|
2015-04-13 |
2022-02-17 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer
|
|
CN107750255B
(zh)
|
2015-04-17 |
2022-08-30 |
安进研发（慕尼黑）股份有限公司 |
用于cdh3和cd3的双特异性抗体构建体
|
|
TWI799849B
(zh)
|
2015-04-24 |
2023-04-21 |
美商安美基公司 |
治療或預防偏頭痛之方法
|
|
DK3303396T5
(da)
|
2015-05-29 |
2024-10-07 |
Bristol Myers Squibb Co |
Antistoffer mod ox40 og anvendelser deraf
|
|
EP3303387A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
CN107922500A
(zh)
|
2015-06-29 |
2018-04-17 |
洛克菲勒大学 |
具有增强的激动剂活性的抗cd40抗体
|
|
PL3319993T3
(pl)
|
2015-07-10 |
2020-07-27 |
Genmab A/S |
Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
|
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
US11236159B2
(en)
|
2015-08-03 |
2022-02-01 |
Novartis Ag |
Methods of treating FGF21-associated disorders
|
|
WO2017027691A1
(en)
|
2015-08-13 |
2017-02-16 |
New York University |
Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
WO2017027685A2
(en)
|
2015-08-13 |
2017-02-16 |
New York University |
Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
|
HRP20210650T1
(hr)
|
2015-09-09 |
2021-05-28 |
Novartis Ag |
Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
|
|
EA038332B1
(ru)
|
2015-09-09 |
2021-08-10 |
Новартис Аг |
Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
|
|
CA2998174A1
(en)
|
2015-09-15 |
2017-03-23 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
|
EP3747472B1
(en)
|
2015-09-15 |
2024-04-03 |
Acerta Pharma B.V. |
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
MX2018006181A
(es)
|
2015-11-23 |
2018-09-24 |
Five Prime Therapeutics Inc |
Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
|
|
WO2017095875A1
(en)
|
2015-11-30 |
2017-06-08 |
Bristol-Myers Squibb Company |
Anti human ip-10 antibodies and their uses
|
|
SI3383920T1
(sl)
|
2015-11-30 |
2024-06-28 |
The Regents Of The University Of California |
Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
|
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
|
RU2018126297A
(ru)
|
2015-12-18 |
2020-01-22 |
Новартис Аг |
Антитела, нацеленные на cd32b, и способы их применения
|
|
UA127495C2
(uk)
|
2015-12-23 |
2023-09-13 |
Амджен Інк. |
Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
|
|
DK3402503T3
(da)
|
2016-01-13 |
2020-12-21 |
Acerta Pharma Bv |
Terapeutiske kombinationer af et antifolat og en btk-hæmmer
|
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
|
EA201891753A1
(ru)
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
|
IL313507A
(en)
|
2016-02-03 |
2024-08-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
|
WO2017137830A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
|
CN108718522A
(zh)
|
2016-02-23 |
2018-10-30 |
赛森生物股份有限公司 |
Il-6拮抗剂制剂及其用途
|
|
ES2985566T3
(es)
|
2016-03-04 |
2024-11-06 |
Univ Rockefeller |
Anticuerpos contra CD40 con actividad agonista mejorada
|
|
EP3423494A1
(en)
|
2016-03-04 |
2019-01-09 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
EP3430058A4
(en)
|
2016-03-15 |
2019-10-23 |
Generon (Shanghai) Corporation Ltd. |
MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
|
|
JP7137474B2
(ja)
|
2016-03-15 |
2022-09-14 |
メルサナ セラピューティクス，インコーポレイティド |
ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
|
|
WO2017161414A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
|
CN109071653A
(zh)
|
2016-03-29 |
2018-12-21 |
詹森生物科技公司 |
用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
|
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
KR20230119259A
(ko)
|
2016-04-15 |
2023-08-16 |
이뮤넥스트, 인크. |
항-인간 vista 항체 및 이의 용도
|
|
US12297266B2
(en)
|
2016-04-18 |
2025-05-13 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
MX392069B
(es)
|
2016-05-09 |
2025-03-21 |
Bristol Myers Squibb Co |
Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
|
|
AU2017283787B2
(en)
|
2016-06-15 |
2020-09-17 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
|
JP2019519536A
(ja)
|
2016-07-01 |
2019-07-11 |
ファイブ プライム セラピューティクス， インコーポレイテッド |
Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法
|
|
PH12018502613B1
(en)
|
2016-07-12 |
2023-02-01 |
H Lundbeck As |
Antibodies specific for hyperphosphorylated tau and methods of use thereof
|
|
CN109757103B
(zh)
|
2016-07-14 |
2024-01-02 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
KR102579850B1
(ko)
|
2016-07-22 |
2023-09-18 |
암젠 인크 |
Fc-함유 단백질의 정제 방법
|
|
CN118108847A
(zh)
|
2016-08-07 |
2024-05-31 |
诺华股份有限公司 |
mRNA介导的免疫方法
|
|
US10947268B2
(en)
|
2016-08-12 |
2021-03-16 |
Bristol-Myers Squibb Company |
Methods of purifying proteins
|
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
|
WO2018049248A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus equipped with bispecific engager molecules
|
|
CA3037961A1
(en)
|
2016-09-30 |
2018-04-05 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il23 specific antibody
|
|
MX2019004371A
(es)
|
2016-10-13 |
2019-11-18 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos.
|
|
WO2018089829A1
(en)
|
2016-11-10 |
2018-05-17 |
Fortis Therapeutics, Inc. |
Cd46-specific effector cells and uses thereof
|
|
MX2019005552A
(es)
|
2016-11-14 |
2019-08-12 |
Amgen Inc |
Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
|
|
JP2020500020A
(ja)
|
2016-11-14 |
2020-01-09 |
ノバルティス アーゲー |
融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用
|
|
BR112018014281A2
(pt)
|
2016-11-15 |
2018-12-18 |
H Lundbeck As |
agentes, usos e métodos para o tratamento da sinucleinopatia
|
|
US11208474B2
(en)
|
2016-11-16 |
2021-12-28 |
Janssen Biotech, Inc. |
Method of treating psoriasis with anti-IL23 specific antibody
|
|
WO2018094143A1
(en)
|
2016-11-17 |
2018-05-24 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
EP3555127B1
(en)
|
2016-12-16 |
2024-12-18 |
H. Lundbeck A/S |
Agents, uses and methods
|
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
|
JP7062669B2
(ja)
|
2016-12-23 |
2022-05-06 |
ブリストル－マイヤーズ スクイブ カンパニー |
改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
|
|
CN110267985B
(zh)
|
2017-01-04 |
2023-05-23 |
H.隆德贝克有限公司 |
用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
|
|
EP3567054A4
(en)
|
2017-01-06 |
2021-03-10 |
ABL Bio Inc. |
ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
|
|
BR112019013953A2
(pt)
|
2017-01-06 |
2020-02-11 |
Abl Bio Inc. |
Anticorpo anti-a-syn e uso do mesmo
|
|
TW201833140A
(zh)
|
2017-01-09 |
2018-09-16 |
美商莫瑞麥克製藥公司 |
抗fgfr抗體及使用方法
|
|
IL313587A
(en)
|
2017-01-17 |
2024-08-01 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
|
|
WO2018140121A1
(en)
|
2017-01-30 |
2018-08-02 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
|
|
SMT202500367T1
(it)
|
2017-02-02 |
2025-11-10 |
Amgen Res Munich Gmbh |
Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t
|
|
MX2019009377A
(es)
|
2017-02-07 |
2019-12-11 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
|
|
KR102572663B1
(ko)
|
2017-02-08 |
2023-09-01 |
노파르티스 아게 |
Fgf21 모방 항체 및 이의 용도
|
|
CA3051839A1
(en)
|
2017-02-17 |
2018-08-23 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
LT3600415T
(lt)
|
2017-03-24 |
2025-12-29 |
Novartis Ag |
Antikūnas prieš ii tipo aktivino receptorių, skirtas naudoti širdies nepakankamumo gydymui
|
|
EP3601362A4
(en)
|
2017-03-30 |
2020-12-16 |
The Johns Hopkins University |
HIGH AFFINITY PROTEIN SUPRAMOLECULAR BINDING SYSTEM FOR BIOMACROMOLECULES PURIFICATION
|
|
CN110709420A
(zh)
|
2017-03-31 |
2020-01-17 |
戊瑞治疗有限公司 |
使用抗gitr抗体的癌症组合疗法
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
UY37726A
(es)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
|
|
PT3624837T
(pt)
|
2017-05-16 |
2025-10-01 |
Five Prime Therapeutics Inc |
Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro
|
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
EA201992502A1
(ru)
|
2017-06-20 |
2020-04-22 |
Эмджен Инк. |
Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
|
|
EP3642238A1
(en)
|
2017-06-21 |
2020-04-29 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (gipr)/glp-1 receptor agonist fusion proteins
|
|
CA3063659A1
(en)
|
2017-06-28 |
2019-01-03 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
|
LT3661562T
(lt)
|
2017-08-04 |
2024-10-25 |
Amgen Inc. |
Cys-mab konjugavimo būdas
|
|
US20200256880A1
(en)
|
2017-08-16 |
2020-08-13 |
The Broad Institute, Inc. |
Neuronal Assay Method Involving Calcineurin
|
|
WO2019036631A1
(en)
|
2017-08-18 |
2019-02-21 |
The Johns Hopkins University |
SUPRAMOLECULAR FILAMENT ASSEMBLIES FOR THE PURIFICATION OF PROTEINS
|
|
EP3681535A1
(en)
|
2017-09-13 |
2020-07-22 |
Five Prime Therapeutics, Inc. |
Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
|
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
JP2021502349A
(ja)
|
2017-11-06 |
2021-01-28 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
|
|
HUE060608T2
(hu)
|
2017-12-05 |
2023-03-28 |
Regeneron Pharma |
Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
|
|
AU2018383679B2
(en)
|
2017-12-11 |
2025-10-09 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
|
EP3725806A4
(en)
|
2017-12-14 |
2022-03-30 |
ABL Bio Inc. |
BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
|
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
SG11202006610YA
(en)
|
2018-01-12 |
2020-08-28 |
Amgen Inc |
Pac1 antibodies and uses thereof
|
|
EP3737700A1
(en)
|
2018-01-12 |
2020-11-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
CA3084370A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
MX2020009265A
(es)
|
2018-03-05 |
2020-10-01 |
Janssen Biotech Inc |
Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
EP3774882A1
(en)
|
2018-03-29 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of purifying monomeric monoclonal antibodies
|
|
UA129352C2
(uk)
|
2018-05-07 |
2025-03-26 |
Генмаб А/С |
Способи лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора та лікарського засобу
|
|
TW202506732A
(zh)
|
2018-05-07 |
2025-02-16 |
丹麥商珍美寶股份有限公司 |
使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
|
|
US20190345245A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
|
WO2019225777A1
(ko)
|
2018-05-23 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-ror1 항체 및 그 용도
|
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
CN113056483B
(zh)
|
2018-07-09 |
2025-08-01 |
戊瑞治疗有限公司 |
结合到ilt4的抗体
|
|
US20200025776A1
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
|
|
CA3107186A1
(en)
|
2018-07-30 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
WO2020025792A1
(en)
|
2018-08-03 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Antibody constructs for cldn18.2 and cd3
|
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
|
HRP20240821T1
(hr)
|
2018-08-27 |
2024-09-27 |
Affimed Gmbh |
Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
EP3853252A1
(en)
|
2018-09-18 |
2021-07-28 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
|
IL326284A
(en)
|
2018-09-24 |
2026-04-01 |
Janssen Biotech Inc |
A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
|
|
JP7644706B2
(ja)
|
2018-10-11 |
2025-03-12 |
アムジエン・インコーポレーテツド |
二重特異性抗体コンストラクトの下流プロセシング
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
CA3117945A1
(en)
|
2018-11-09 |
2020-05-14 |
University Of Massachusetts |
Anti-cfae antibodies and methods of use
|
|
CN113316590B
(zh)
|
2018-11-16 |
2025-02-28 |
百时美施贵宝公司 |
抗nkg2a抗体及其用途
|
|
IL283192B2
(en)
|
2018-11-20 |
2025-10-01 |
Janssen Biotech Inc |
A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
|
|
MA54562A
(fr)
|
2018-12-18 |
2021-10-27 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
JP7689074B2
(ja)
|
2019-01-15 |
2025-06-05 |
ヤンセン バイオテツク，インコーポレーテツド |
若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
|
|
CN113396162B
(zh)
|
2019-01-22 |
2024-08-16 |
百时美施贵宝公司 |
抗IL-7Rα亚基的抗体及其用途
|
|
WO2020152544A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
|
CA3131953A1
(en)
|
2019-03-01 |
2020-09-10 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
|
KR20210141998A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 제조 방법
|
|
EA202192505A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
|
EP3938384A4
(en)
|
2019-03-14 |
2022-12-28 |
Janssen Biotech, Inc. |
PREPARATION PROCEDURES FOR THE PREPARATION OF ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
|
|
WO2020183269A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
|
JP2022526493A
(ja)
|
2019-03-18 |
2022-05-25 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
|
|
US12174161B2
(en)
|
2019-03-29 |
2024-12-24 |
Bristol-Myers Squibb Company |
Methods of measuring hydrophobicity of chromatographic resins
|
|
JP7805788B2
(ja)
|
2019-05-23 |
2026-01-26 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
|
|
JP7500619B2
(ja)
|
2019-05-30 |
2024-06-17 |
アムジエン・インコーポレーテツド |
抗体の二量体化を促進するためのヒンジ領域の操作
|
|
JP2022536279A
(ja)
|
2019-06-03 |
2022-08-15 |
ヤンセン バイオテツク，インコーポレーテツド |
乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
|
|
MX2021014882A
(es)
|
2019-06-03 |
2022-03-25 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
|
|
MA56124A
(fr)
|
2019-06-04 |
2022-04-13 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
|
|
US11066469B2
(en)
|
2019-06-12 |
2021-07-20 |
Novartis Ag |
Natriuretic peptide receptor 1 antibodies and methods of use
|
|
MX2021014644A
(es)
|
2019-06-13 |
2022-04-06 |
Amgen Inc |
Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
|
|
US20220363770A1
(en)
|
2019-06-28 |
2022-11-17 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
|
WO2021014389A1
(en)
|
2019-07-24 |
2021-01-28 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
|
AU2020323901A1
(en)
|
2019-07-26 |
2022-02-24 |
Amgen Inc. |
Anti-IL13 antigen binding proteins
|
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
|
US20220306741A1
(en)
|
2019-09-10 |
2022-09-29 |
Amgen Inc. |
Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
WO2021076930A1
(en)
|
2019-10-18 |
2021-04-22 |
The Regents Of The University Of California |
Plxdc activators and their use in the treatment of blood vessel disorders
|
|
WO2021091815A1
(en)
|
2019-11-04 |
2021-05-14 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
|
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
|
|
TW202132343A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
|
|
ES3040852T3
(en)
|
2019-11-08 |
2025-11-05 |
Amgen Inc |
Engineering charge pair mutations for pairing of hetero-igg molecules
|
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
|
AU2020386005A1
(en)
|
2019-11-19 |
2022-05-26 |
Amgen Inc. |
Novel multispecific antibody format
|
|
EP4077376A2
(en)
|
2019-12-19 |
2022-10-26 |
Quidel Corporation |
Monoclonal antibody fusions
|
|
JP7758672B2
(ja)
|
2019-12-20 |
2025-10-22 |
ノヴァロック バイオセラピューティクス， リミテッド |
抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
|
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
AU2020414409A1
(en)
|
2019-12-27 |
2022-06-16 |
Affimed Gmbh |
Method for the production of bispecific FcyRIIl x CD30 antibody construct
|
|
KR20230020379A
(ko)
|
2020-01-06 |
2023-02-10 |
하이파이바이오 (에이치케이) 리미티드 |
항-tnfr2 항체 및 이의 용도
|
|
CN120647763A
(zh)
|
2020-01-07 |
2025-09-16 |
高诚生物医药公司 |
抗半乳糖凝集素-9抗体及其用途
|
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
|
WO2021188851A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
|
CN115461363A
(zh)
|
2020-05-01 |
2022-12-09 |
诺华股份有限公司 |
免疫球蛋白变体
|
|
CN116096758A
(zh)
|
2020-05-01 |
2023-05-09 |
诺华股份有限公司 |
工程化免疫球蛋白
|
|
US20210347880A1
(en)
|
2020-05-05 |
2021-11-11 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
|
IL298389A
(en)
|
2020-05-21 |
2023-01-01 |
Janssen Biotech Inc |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
US20240209085A1
(en)
|
2020-05-29 |
2024-06-27 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
|
EP4171652A1
(en)
|
2020-06-29 |
2023-05-03 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2022013745A1
(en)
|
2020-07-13 |
2022-01-20 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
|
US20220073603A1
(en)
|
2020-07-30 |
2022-03-10 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
|
|
EP4192511A1
(en)
|
2020-08-07 |
2023-06-14 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting cd46 and methods of use thereof
|
|
CN116724051A
(zh)
|
2020-08-10 |
2023-09-08 |
上海寻百会生物技术有限公司 |
用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
|
|
US20230322955A1
(en)
|
2020-08-20 |
2023-10-12 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
|
EP4208259A2
(en)
|
2020-09-04 |
2023-07-12 |
NovaRock Biotherapeutics, Ltd. |
Nectin-4 antibodies and uses thereof
|
|
US20230374162A1
(en)
|
2020-10-07 |
2023-11-23 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
|
CN116368154A
(zh)
|
2020-10-08 |
2023-06-30 |
阿菲姆德股份有限公司 |
三特异性结合剂
|
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
|
UY39507A
(es)
|
2020-11-06 |
2022-03-31 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
TW202225188A
(zh)
|
2020-11-06 |
2022-07-01 |
德商安美基研究（慕尼黑）公司 |
與ｃｄ３結合的多肽構建體
|
|
WO2022096704A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
WO2022103773A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
|
AU2021383611A1
(en)
|
2020-11-17 |
2023-06-29 |
Peter Maccallum Cancer Institute |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
|
IL305802A
(en)
|
2021-03-12 |
2023-11-01 |
Janssen Biotech Inc |
A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
|
|
EP4305062A1
(en)
|
2021-03-12 |
2024-01-17 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
|
US20250282887A1
(en)
|
2021-04-02 |
2025-09-11 |
Amgen Inc. |
Mageb2 binding constructs
|
|
US20240199725A1
(en)
|
2021-04-16 |
2024-06-20 |
Korea University Research And Business Foundation |
Human antibody targeting covid-19 virus
|
|
MX2023012324A
(es)
|
2021-04-20 |
2023-10-30 |
Amgen Inc |
Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
|
|
WO2022232376A1
(en)
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
|
JP2024518369A
(ja)
|
2021-05-06 |
2024-05-01 |
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング |
増殖性疾患で使用されるｃｄ２０及びｃｄ２２標的化抗原結合分子
|
|
EP4367136A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
|
JP2024527581A
(ja)
|
2021-07-09 |
2024-07-25 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ１２／ｉｌ２３抗体組成物を生産するための製造方法
|
|
US12534524B2
(en)
|
2021-07-09 |
2026-01-27 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-TNF antibody compositions
|
|
CA3216098A1
(en)
|
2021-07-30 |
2023-02-02 |
Uwe Reusch |
Duplexbodies
|
|
MX2024005080A
(es)
|
2021-10-29 |
2024-05-13 |
Seagen Inc |
Metodos para tratar cancer con una combinacion de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-cd30-farmaco.
|
|
EP4423126B1
(en)
|
2021-10-29 |
2026-05-06 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
US20260070986A1
(en)
|
2021-11-03 |
2026-03-12 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
IL312515A
(en)
|
2021-11-03 |
2024-07-01 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
EP4433501A1
(en)
|
2021-11-15 |
2024-09-25 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
|
JP2025512860A
(ja)
|
2022-03-30 |
2025-04-22 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法
|
|
IL316174A
(en)
|
2022-04-26 |
2024-12-01 |
Novartis Ag |
Multiple specific antibodies targeting IL-13 and IL-18
|
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
|
EP4522651A1
(en)
|
2022-05-12 |
2025-03-19 |
Amgen Research (Munich) GmbH |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
EP4526342A1
(en)
|
2022-05-18 |
2025-03-26 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
|
CA3261603A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
ANTIBODY-DRUG CONJUGATES
|
|
TW202421650A
(zh)
|
2022-09-14 |
2024-06-01 |
美商安進公司 |
雙特異性分子穩定組成物
|
|
AU2023383916A1
(en)
|
2022-11-22 |
2025-07-10 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
|
JP2025541340A
(ja)
|
2022-12-16 |
2025-12-18 |
フィアン セラピューティクス エルティーディー |
Ｃｕｂ ｄｏｍａｉｎ－ｃｏｎｔａｉｎｉｎｇ ｐｒｏｔｅｉｎ １（ｃｄｃｐ１）に対する抗体およびその使用
|
|
EP4658687A1
(en)
|
2023-01-31 |
2025-12-10 |
University of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
UY40797A
(es)
|
2023-06-14 |
2024-12-31 |
Amgen Inc |
Moléculas captadoras de enmascaramiento de células t
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
WO2025085489A1
(en)
|
2023-10-17 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
|
|
WO2025147575A1
(en)
|
2024-01-06 |
2025-07-10 |
Generate Biomedicines, Inc. |
Anti-il-13 antibodies and methods of use thereof
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
TW202548027A
(zh)
|
2024-01-23 |
2025-12-16 |
美商安進公司 |
用於調節單株抗體電荷變體之方法
|
|
WO2025174974A1
(en)
|
2024-02-14 |
2025-08-21 |
Bristol-Myers Squibb Company |
Anti-cd33 antibodies and uses thereof
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025199030A1
(en)
|
2024-03-18 |
2025-09-25 |
Amgen Inc. |
Glp-1 receptor agonists and their medical use
|
|
CA3249015A1
(en)
|
2024-03-20 |
2025-10-31 |
Janssen Biotech, Inc. |
Methods of treating crohn’s disease with anti-il23 specific antibody
|
|
WO2025255349A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Multispecific anti-cd40 / anti-fap antibodies and uses thereof
|
|
WO2025255405A1
(en)
|
2024-06-06 |
2025-12-11 |
Bristol-Myers Squibb Company |
Anti-fap antibodies and uses thereof
|
|
WO2025262604A1
(en)
|
2024-06-17 |
2025-12-26 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
WO2025262641A1
(en)
|
2024-06-19 |
2025-12-26 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
|
CA3258952A1
(en)
|
2024-06-27 |
2026-03-01 |
Janssen Biotech, Inc. |
Methods of treating ulcerative colitis with anti-il23 specific antibody
|
|
US20260078179A1
(en)
|
2024-07-18 |
2026-03-19 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|
|
WO2026078443A1
(en)
|
2024-10-11 |
2026-04-16 |
Pheon Therapeutics Ltd. |
Antibody drug conjugates that bind cdcp1 and uses thereof
|